Biotech · Private company
GV20 Therapeutics
Track this companyFree. Adds GV20 Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- GV20-0251Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- GV20-0251 and Pembrolizumab [KEYTRUDA®]Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesPHASE1_PHASE2 · RECRUITING · started Mar 23, 2023ClinicalTrials.gov NCT05669430 · fetched Nov 12, 2026